Host-Modulation Therapy for Peri-Implantitis: Current Systemic and Future Medical Applications Recognizing the Potential Systemic Impact of Peri-Implantitis on Systemic Disease
Oral Science thanks Oral Health Group for the article published in the 2021 October edition of it's magazine.
Host-Modulation Therapy for Peri-Implantitis: Current Systemic and Future Medical Applications Recognizing the Potential Systemic Impact of Peri-Implantitis on Systemic Disease written by Steve Chang, DDS, MSc; Michael Glogauer, DDS, Dip Perio, PhD, FRCD(C); Lorne Golub, DMD, MSc, DSc, MDSc; Joseph Bacigalupo, DDS; Timo Sorsa, DDS, Dip Perio, PhD; Philip M. Preshaw, BDS, FDSRCSEd, PhD, EDS; Hsi-Ming-Lee, PhD Howard C. Tenenbaum, DDS, Dip Perio, PhD, FRCD(C)
The summary is the following:
We propose that inflammatory disease about implants should have the same and possibly greater impact on the incidence and severity of systemic diseases that have already been associated with periodontitis. Long-term administration of Periostat® (3-17 years) might effectively prevent and treat peri-implantitis in combination with resveratrol and Prevora®.